Johnson & Johnson (JNJ) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus is a beatable bar on revenue given JNJ's Q1 beat and raised guidance, but the EPS comparison is complicated by heavy H1 investment spend; the single biggest swing factor is the pace of ICOTYDE and INLEXZO launch ramp relative to still-cautious Street estimates.

Heading into Q2 2026, JNJ's setup is broadly favorable but nuanced. The company raised full-year 2026 operational sales guidance to 5.9%–6.9% (midpoint $100.2B) after Q1's 6.4% operational growth, and consensus revenue of ~$25.1B implies ~6% YoY growth — a bar that looks achievable given the STELARA headwind is moderating and newly launched products are ramping. Management explicitly flagged that heavier investment is front-loaded in H1, which explains why the EPS consensus of ~$2.86 sits below Q2 2025's $2.77 actuals on an adjusted basis — the Street is not expecting a clean EPS beat, making revenue and segment growth the primary read. Estimate revisions have been modestly positive since the Q1 print, with the FY2026 consensus EPS of ~$11.58 sitting near the top of management's raised guidance range of $11.30–$11.50 (reported basis $11.55 midpoint), suggesting the Street has already priced in a solid year. The stock has rallied ~5.7% since the Q1 earnings date (April 14) to $253.85, roughly in line with XLV (+6.4%) and modestly lagging SPY (+8.3%), meaning the stock has not dramatically pre-run the print. The key wildcard is ICOTYDE — management called it a potential top-ever product at launch in late March 2026, and any early commercial data point (patient hub volumes, payer coverage wins, or physician adoption metrics) that exceeds the Street's conservative ~$44M Q2 consensus estimate could be a meaningful positive catalyst.

2. KPIs & Consensus Expectations

Key Takeaway: Revenue is a manageable bar given the STELARA headwind is easing and new launches are ramping; DARZALEX and TREMFYA are the two biggest swing-factor KPIs — both carry high Street expectations and any upside there would likely drive the stock on results day.

Table 1 — Q2 2026 Current Quarter Snapshot (Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. Q2 2026 consensus estimates as of July 14, 2026. YoY change calculated vs. Q2 2025 actuals. ICOTYDE launched March 2026; Q2 2026 consensus ~$44M per Visible Alpha.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Pattern: JNJ has beaten revenue consensus in all 8 of the last 8 quarters, with an average surprise of ~1.5%; EPS beats are nearly as consistent (7 of 8 quarters), with the sole miss in Q4 2025 being a rounding-level miss of just -0.4%. The Street has historically set a beatable bar on both KPIs. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised full-year guidance at Q1 and struck a notably confident tone on new launches; the posture has shifted more bullish since last earnings, with ICOTYDE, INLEXZO, and TREMFYA all cited as upside drivers that the Street is underestimating.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: FY2026 consensus EPS of ~$11.58 sits just above the top of management's raised guidance range ($11.50 operational), suggesting the Street has already priced in a solid year; revenue estimates have drifted modestly higher since Q1 as new launch momentum builds.

Source: Visible Alpha Consensus and Actuals Data; JNJ Q1 2026 Earnings Release (April 14, 2026). Pre-Q1 estimates are approximate baselines based on prior consensus snapshots.

5. Stock Performance

Key Takeaway: JNJ has gained ~5.7% since Q1 earnings (April 14) to $253.85, modestly lagging XLV (+6.4%) and SPY (+8.3%) — the stock has not dramatically pre-run the print, leaving room for a positive reaction if Q2 results and guidance impress.

JNJ vs. XLV vs. SPY — Indexed Price Performance Since Q1 2026 Earnings (April 14, 2026 = 100). Source: Yahoo Finance / Stock Price Data.

JNJ opened at $240.10 on April 14 (Q1 earnings day) and closed at $253.85 on July 14, 2026, a gain of +$13.75 / +5.7%. Over the same period, XLV gained +6.4% and SPY gained +8.3%. JNJ's relative underperformance vs. the broader market reflects sector rotation headwinds and some investor caution around tariff impacts on MedTech margins, but the stock is not stretched heading into the print. The stock traded as low as $221.32 (May 8) before recovering sharply, with the recent rally to the $253–$267 range driven by positive pipeline news (TREMFYA label expansion, ICOTYDE one-year data, RYBREVANT HNSCC data) and broader healthcare sector strength. Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments Since Q1 Earnings (April 14 – July 14, 2026)

Key Takeaway: The post-Q1 news flow has been overwhelmingly positive — multiple regulatory approvals, strong pipeline data readouts, and a major U.S. manufacturing investment announcement all reinforce the bull case heading into Q2.

• ICOTYDE (icotrokinra) FDA Approval & Launch (March 2026, reported at Q1): Approved as first-and-only IL-23-targeted oral peptide for first-line plaque psoriasis. Full commercial launch same day as approval. One-year data (May 2026) confirmed lasting skin clearance and favorable safety. Management calls it a potential top-ever product.
• TREMFYA Label Expansion — Structural Joint Damage (May 28, 2026): FDA approved label expansion cementing TREMFYA as the only IL-23 inhibitor proven to help stop further joint damage in psoriatic arthritis patients. Accelerates psoriasis and PsA market share.
• TREMFYA — Perianal Fistulizing Crohn's Disease Data (May 2026): New FUSION trial data presented at DDW showing TREMFYA is the first IL-23 to show efficacy in perianal fistulizing Crohn's disease (~25% of CD population), a population historically treated only with Remicade.
• INLEXZO J-Code Reimbursement (April 1, 2026): Permanent J-code effective April 1 enabling broader patient access. Management noted a near-doubling of insertions and meaningful increase in providers utilizing the product in the first two weeks post-J-code. NCCN Category 2A guidelines also received for papillary disease.
• RYBREVANT FASPRO — HNSCC Pivotal Data (May 2026): Pivotal OrigAMI-4 second-line HNSCC data presented at ASCO 2026 as an oral abstract; management indicated data could support a filing given breakthrough designation. RYBREVANT FASPRO (SC formulation) received US approval in January 2026.
• TECVAYLI + DARZALEX FASPRO FDA Approval (March 2026): Approved for second-line relapsed/refractory multiple myeloma (at least one prior line) in 55 days under Commissioner's National Priority Voucher program, based on Phase 3 MajesTEC-3 data showing statistically significant improvements in PFS and OS.
• NIPOCALIMAB (IMAAVY) — Multiple Data Readouts (May–June 2026): Positive Phase 2/3 data in warm autoimmune hemolytic anemia (wAIHA) and SLE presented; new data at EAN 2026 reinforcing sustained disease control in generalized myasthenia gravis.
• JNJ-4804 Co-Antibody (DUET) Phase 2b Data (May 2026): Positive DUET data in UC and CD presented at DDW; Phase 3 DUET ENCORE trials now being initiated. Positioned as potential first co-antibody therapeutic in IBD.
• VARIPULSE Pro CE Mark (March 2026) & PERSIGMA Trial (April 2026): Second-generation VARIPULSE Pro received CE Mark in Europe. PERSIGMA randomized head-to-head trial vs. FARAPULSE initiated in April 2026 in persistent AFib. CARTOSOUND SONATA launched at HRS 2026.
• Firefly Bio Acquisition (June 2026): JNJ announced acquisition of Firefly Bio to expand oncology pipeline with novel degrader antibody conjugate platform.
• U.S. Vision Manufacturing Investment (June 2026): JNJ announced investment of more than $1 billion to strengthen U.S. Vision manufacturing in Jacksonville, Florida.
• Dual Energy THERMOCOOL SMARTTOUCH SF FDA Approval (July 2026): FDA approved the Dual Energy THERMOCOOL SMARTTOUCH SF platform, expanding JNJ's multimodal PFA/RF ablation portfolio.

7. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peer commentary since Q1 earnings is broadly constructive for JNJ's Q2 setup — immunology demand remains robust, the EP/PFA market is growing rapidly, and MedTech procedure volumes are healthy; the key risk flagged across peers is tariff-related margin pressure in MedTech and China VBP headwinds in EP.

Note: All peer commentary below is sourced from conference calls and investor events occurring after JNJ's Q1 2026 earnings (April 14, 2026) and pertains to current Q2 2026 market conditions or forward-looking commentary about the current reporting period. Prior-quarter results commentary has been excluded.

7.1 AbbVie (ABBV) — Goldman Sachs Global Healthcare Conference (June 9, 2026) & Apogee Acquisition Call (June 22, 2026)

Read-Through Relevance: Immunology (IL-23 / IL-17 class dynamics, IBD market, psoriasis), Oncology (multiple myeloma), Neuroscience (antidepressant market for CAPLYTA).

• Immunology demand remains strong: AbbVie's commentary at Goldman Sachs confirmed continued robust demand in the immunology space, with the IL-23 class in IBD still in early innings of penetration. AbbVie noted that class penetration in IBD remains well below the addressable patient population, consistent with JNJ's own framing that only ~20–25% of addressable IBD patients are on IL-23 therapy — a significant runway for TREMFYA's IBD franchise.
• Psoriasis market expanding with oral options: AbbVie's acquisition of Apogee Therapeutics (announced June 22, 2026) — focused on next-generation biologics for atopic dermatitis and other inflammatory diseases — signals continued confidence in the immunology/dermatology market's long-term growth. This is a positive read-through for ICOTYDE's market opportunity as the first oral IL-23 receptor blocker in psoriasis.
• Biosimilar competition commentary: AbbVie's discussion of Skyrizi (risankizumab, an IL-23 inhibitor) growth trajectory in IBD and psoriasis is directly relevant to TREMFYA's competitive positioning. AbbVie's continued strong Skyrizi performance validates the IL-23 class growth but also signals that TREMFYA faces a well-resourced competitor in the IBD space.

7.2 Boston Scientific (BSX) — Bernstein Strategic Decisions Conference (May 27, 2026)

Read-Through Relevance: Electrophysiology / PFA ablation market dynamics, MedTech procedure volumes, competitive landscape for JNJ's Biosense Webster EP franchise.

• PFA is the dominant ablation modality and growing fast: BSX CEO Michael Mahoney confirmed that PFA "has clearly become the market-leading therapeutic catheter," with U.S. PFA utilization estimated at ~70% in 2025 and approaching ~80% in 2026. This is a strong positive read-through for JNJ's VARIPULSE platform, which is gaining share in the PFA market.
• BSX expects to maintain PFA market share leadership but acknowledges competition: Mahoney stated BSX "provided more space for some additional market share reduction as competitors continue to launch," explicitly acknowledging that JNJ's VARIPULSE and other entrants are taking share. JNJ management noted it achieved total therapeutic unit leadership in the U.S. EP market in late 2025 — BSX's commentary validates that the competitive dynamic is real and ongoing.
• International PFA penetration is still low — a growth opportunity: BSX noted OUS PFA utilization at ~50% and "very low penetration so far in China." This is consistent with JNJ's own framing of international EP as a significant growth opportunity, though China VBP headwinds remain a risk for H2 2026.
• MedTech procedure volumes healthy: BSX's overall commentary on procedure volumes was constructive, with no signs of demand deterioration in cardiac procedures. This is a positive read-through for JNJ's broader MedTech segment heading into Q2.

7.3 Medtronic (MDT) — FQ4 2026 Earnings Call (May 20 / June 3, 2026)

Read-Through Relevance: MedTech demand environment, surgical procedure volumes, tariff impacts on MedTech margins, EP competitive dynamics.

• Surgical procedure volumes remain solid: MDT's FQ4 2026 results (fiscal year ending April 2026) showed continued healthy procedure volumes across surgical and cardiovascular categories. MDT's commentary on procedure demand is a positive read-through for JNJ's Surgery and Cardiovascular MedTech segments.
• Tariff headwinds are real but manageable: MDT flagged tariff-related cost pressures in its MedTech cost of goods, consistent with JNJ's own Q1 commentary that MedTech margin declined from 25.9% to 22.3% "primarily driven by the impact of tariffs." MDT's ability to manage through tariffs with pricing and supply chain actions provides a template, but also confirms the headwind is sector-wide and not JNJ-specific.
• EP market competitive intensity acknowledged: MDT's EP commentary acknowledged the competitive shift toward PFA and away from traditional RF ablation, validating JNJ's VARIPULSE momentum. MDT's own PFA product development timeline suggests JNJ and BSX will continue to be the primary PFA competitors in the near term.

7.4 Gilead Sciences (GILD) — Bernstein Strategic Decisions Conference (May 28, 2026) & Goldman Sachs Global Healthcare Conference (June 9, 2026)

Read-Through Relevance: Oncology market dynamics, HIV/antiviral market (limited direct overlap), broader biopharma demand environment.

• Oncology demand environment remains robust: GILD's commentary at both Bernstein and Goldman Sachs conferences highlighted continued strong demand in oncology, particularly in hematologic malignancies. This is a positive read-through for JNJ's DARZALEX and CARVYKTI franchises in multiple myeloma, where GILD's Trodelvy and other oncology assets compete in adjacent tumor types.
• Biopharma pricing environment stable: GILD's commentary on the drug pricing environment (IRA implications, payer dynamics) was measured — no new acute pricing pressures flagged for Q2 2026. This is broadly constructive for JNJ's Innovative Medicine segment, which faces ongoing IRA-related pricing scrutiny on DARZALEX and other products.

7.5 Bristol-Myers Squibb (BMY) — Goldman Sachs Global Healthcare Conference (June 9, 2026)

Read-Through Relevance: Multiple myeloma market (ABECMA vs. CARVYKTI), oncology demand, neuroscience (antidepressant market for CAPLYTA).

• Multiple myeloma CAR-T market growing but competitive: BMY's commentary on ABECMA (ide-cel, a BCMA-targeted CAR-T) at Goldman Sachs acknowledged the competitive pressure from JNJ's CARVYKTI (cilta-cel), which has been taking share in the relapsed/refractory multiple myeloma market. BMY's discussion of earlier-line expansion strategies for ABECMA mirrors JNJ's own strategy with CARVYKTI — both companies are pursuing smoldering myeloma and earlier-line indications. The overall CAR-T market commentary was constructive, with demand exceeding manufacturing capacity as a key constraint.
• Neuroscience / antidepressant market dynamics: BMY's neuroscience portfolio commentary (including Cobenfy for schizophrenia) highlighted continued strong demand for novel CNS therapies. This is a positive read-through for JNJ's CAPLYTA (lumateperone, acquired via Intra-Cellular), which is in the early stages of its commercial ramp post-acquisition and targeting MDD and bipolar disorder.
• Oncology pricing and access: BMY flagged no new acute payer access issues for its oncology portfolio in Q2, a constructive read-through for JNJ's oncology franchise.

7.6 Regeneron (REGN) — Goldman Sachs Global Healthcare Conference (June 8, 2026)

Read-Through Relevance: Dermatology / immunology market (Dupixent vs. ICOTYDE/TREMFYA), multiple myeloma (BCMA programs), biosimilar competition dynamics.

• Dermatology market remains large and underpenetrated: REGN's CFO highlighted Dupixent's "continued very strong growth trajectory" and noted the product is approved in 9 distinct diseases. REGN is developing a long-acting IL-13 antibody as a next-generation Dupixent follow-on. This validates the dermatology/immunology market's continued growth, a positive read-through for ICOTYDE's launch opportunity in psoriasis (a different mechanism but overlapping patient population).
• Biosimilar IP defense strategy: REGN's detailed discussion of Dupixent's IP estate (composition of matter patent expiring March 2031, additional patents into mid-2040s) is relevant context for JNJ's own biosimilar exposure on DARZALEX and TREMFYA. REGN's aggressive IP defense posture is consistent with JNJ's approach.
• Multiple myeloma BCMA opportunity: REGN's CFO flagged "BCMA in myeloma" as one of the programs he is most enthusiastic about, validating the commercial opportunity in the BCMA-targeted therapy space where JNJ's CARVYKTI and TECVAYLI compete. REGN's entry into this space (via its BCMA bispecific program) is a longer-term competitive consideration but not an immediate Q2 headwind.

7.7 Amgen (AMGN) — Goldman Sachs Global Healthcare Conference (June 9, 2026) & Jefferies Global Healthcare Conference (June 4, 2026)

Read-Through Relevance: Oncology / multiple myeloma (bispecific antibodies), immunology market, biosimilar competition dynamics.

• Bispecific antibody market in multiple myeloma is expanding: AMGN's commentary on its bispecific antibody portfolio (including BLINCYTO and its myeloma programs) at both Goldman and Jefferies conferences highlighted continued strong demand for bispecific therapies in hematologic malignancies. This is a positive read-through for JNJ's TECVAYLI and TALVEY bispecific franchises in multiple myeloma.
• Biosimilar competition in immunology: AMGN's biosimilar business commentary (including biosimilars to Humira and other immunology products) is relevant context for the competitive environment JNJ faces with STELARA biosimilars. AMGN's data on biosimilar uptake dynamics suggests the STELARA headwind for JNJ is well-understood and largely priced in by the Street.

7.8 Merck (MRK) — Goldman Sachs Global Healthcare Conference (June 9, 2026) & ASCO Investor Event (June 1, 2026)

Read-Through Relevance: Oncology market (KEYTRUDA combinations, lung cancer, HNSCC), immunology, biopharma pricing environment.

• Oncology demand environment remains strong: MRK's ASCO investor event and Goldman Sachs commentary highlighted continued robust demand for oncology therapies, particularly in lung cancer and HNSCC. This is directly relevant to JNJ's RYBREVANT franchise — MRK's KEYTRUDA is a combination partner for RYBREVANT in lung cancer (MARIPOSA data), and MRK's HNSCC commentary validates the market opportunity for RYBREVANT's OrigAMI-4 HNSCC program.
• HNSCC market opportunity validated: MRK's discussion of KEYTRUDA's role in HNSCC (first-line and second-line) at ASCO 2026 validates the market opportunity that JNJ is targeting with RYBREVANT FASPRO in second-line HNSCC. MRK's data on the low historical response rate bar in second-line HNSCC is consistent with JNJ management's framing that RYBREVANT's OrigAMI-4 data "could support a filing."
• IRA / drug pricing: MRK's commentary on IRA drug pricing negotiations (KEYTRUDA is subject to IRA price negotiation) flagged manageable near-term impact but longer-term uncertainty. JNJ faces similar IRA exposure on DARZALEX and other products; MRK's measured tone suggests no acute Q2 pricing shock.

7.9 Zimmer Biomet (ZBH) — Goldman Sachs Global Healthcare Conference (June 8, 2026)

Read-Through Relevance: Orthopedic / surgical procedure volumes, MedTech demand environment, tariff impacts on MedTech.

• Surgical procedure volumes healthy in Q2: ZBH's commentary at Goldman Sachs confirmed healthy orthopedic procedure volumes in Q2 2026, with no signs of demand deterioration. This is a positive read-through for JNJ's Surgery MedTech segment (Advanced Surgery, General Surgery), which benefits from the same underlying procedure volume trends.
• Tariff headwinds acknowledged but manageable: ZBH flagged tariff-related cost pressures consistent with the broader MedTech sector. ZBH's ability to partially offset tariff headwinds through pricing and operational efficiency is a constructive read-through for JNJ's MedTech margin trajectory in Q2, though JNJ's Q1 MedTech margin decline (25.9% to 22.3%) suggests the headwind is meaningful.
• Surgical robotics market developing: ZBH's commentary on the surgical robotics competitive landscape is relevant context for JNJ's Ottava robotic surgical system, which has a De Novo FDA submission pending. ZBH's experience suggests the robotics market is developing but requires significant commercial investment.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: Insider activity since Q1 earnings is limited to a single open-market sale by the Chief Transformation Officer — no insider buying has been disclosed, and the sale is modest in size relative to total holdings, suggesting no strong directional signal from insiders heading into Q2.

Source: SEC Form 4 Filings / Insider Transaction Data. Window: April 14, 2026 – July 14, 2026. The sale of 10,000 shares by the Chief Transformation & Risk Officer on June 11, 2026 represents ~8.0% of her post-transaction holdings of 114,288 shares. The transaction was not executed under a 10b5-1 pre-planned trading program. No insider purchases were disclosed during the period. The limited insider activity and absence of buying does not provide a strong directional signal, though the lack of any large-scale selling by senior executives (CEO, CFO, segment heads) is broadly neutral-to-constructive.

Disclosures & Data Sources

• Visible Alpha Consensus and Actuals Data — KPI consensus estimates, actuals, and beat/miss history (Tables 1 and 2).
• JNJ Q1 2026 Earnings Call Transcript (April 14, 2026) — Guidance, management commentary, and segment detail.
• JNJ Q1 2026 Earnings Release / 8-K (April 14, 2026) — Reported financials and guidance update.
• JNJ Press Releases (April 14 – July 14, 2026) — Material news and developments.
• Peer Conference Call Transcripts (May–June 2026) — ABBV, BSX, MDT, GILD, BMY, REGN, AMGN, MRK, ZBH — sourced from financial documents database.
• Stock Price Data (Yahoo Finance) — JNJ, XLV, SPY daily closing prices April 13 – July 14, 2026.
• SEC Form 4 Filings / Insider Transaction Data — Insider transactions April 14 – July 14, 2026.
• This document is prepared for informational purposes only and does not constitute investment advice. All consensus estimates are as of July 14, 2026 and subject to change.